Clinical trial
Prospective Observational Study of Febrile Neutropenia (FN) and Pegfilgrastim Primary Prophylaxis in Breast Cancer and Non-Hodgkin's Lymphoma Patients Receiving High (>20%) FN-risk Chemotherapy
NCT02178475 is registered in ClinicalTrials.gov with Amgen as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Prospective Observational Study of Febrile Neutropenia (FN) and Pegfilgrastim Primary Prophylaxis in Breast Cancer and Non-Hodgkin's Lymphoma Patients Receiving High (>20%) FN-risk Chemotherapy
- Lead sponsor
- Amgen
- Phase
- Observational
- Overall status
- Completed
- Start date
- July 18, 2014
- Completion date
- October 28, 2016
- Enrollment
- 943 (actual)
- Sites
- 74
Conditions
As the registry lists them; a condition with its own page is linked.